† These authors contributed equally to this work.
D
rug delivery using nanoscale liposomal vehicles has recently emerged as a highly promising strategy for cancer treatments with many advantages over conventional small-molecule chemotherapy. 1 Such advantages, arising from the ability of liposomes to encapsulate cytotoxic drugs and protect them from enzymatic degradation and renal clearance, include improved pharmacokinetics and reduced adverse side effects often associated with toxic small-molecule anticancer agents. 2 Together with the use of ion gradientmediated (IGM) loading methodology, liposomal cores can be infused with very high density of drugs (0.3À0.5 drug-to-lipid molar ratio, often beyond the aqueous solubility of these drugs). 3, 4 These features allow for the delivery of a high dosage of pharmaceuticals while maintaining low side effects and are responsible in part for the clinical successes of a number of liposomal formulations in the treatment of cancer. 1, 5 Recently, an IGM-based method has been developed to load arsenic trioxide ( 12 better than free ATO, the Ni II and As III ions are not released in a concerted manner in vitro. In solution-based release assays, 6, 12 only As III was released readily as membrane-permeable arsenous acid, while the Ni II ions are still trapped inside the intact liposomal vehicles after 48 h of incubation under acidic conditions. We previously demonstrated the insertion/ cross-linking of cholesterol-terminated poly-(acrylic acid) as a facile drop-in modification strategy for stabilizing drug-loaded liposomes without hampering the encapsulated drug. 15 The resulting polymer-caged nanobins (PCN) possess pH-sensitive polymer shells that can enhance the release of the encapsulated drugs in acidic environments commonly found in tumor interstitium 16 and cellular endosomes. 17 As such, we hypothesize that the PCN platform can be used to modulate the therapeutic efficacy of the [Ni II ,
As III ]-encapsulated liposome system via acid-triggered release of both As III and Ni II ions at the same time.
Herein, we demonstrate the versatility of the pH-sensitive polymer cage of the PCN platform in inducing release of both pharmacologically active types of cargo (namely As III and Ni
II
) that have been co-encapsulated in a single liposomal core (Scheme 1), which leads to better pro-apoptotic activity in cancer cell lines. Molecular modeling further confirms that this chemomechanical release property of the PCN arises from stimuli-responsive conformational change of the polymer cage, which in turn perturbs the lipid membrane. Thus, triggered drug release in PCNs that in a quite different manner than that in the bare liposomes, BL(Ni,As), which have no PEG or other polymer coating. The resulting concurrent release of As III (HAsO 3 ) ] n , inside the liposomal core (Scheme S1 in the Supporting Information (SI)). 6 Using the resulting BL (Ni,As) (arsenic-to-lipid ratio = 0.45 ( 0.03 mol/mol as determined by inductively coupled plasma optical emission spectroscopy, ICP-OES; D H (hydrodynamic diameter) = 98 ( 7 nm and ζ (zeta potential) = À4.1 mV as measured by dynamic light scattering (DLS) at 25°C) as a template, PCN(Ni,As) was subsequently constructed via the insertion of cholesterol-terminated poly(acrylic acid) (Chol-PAA, M n ≈ 3700 Da) into the membrane, followed by in situ cross-linking with 2,2 0 -(ethylenedioxy)-bis(ethylamine) 19 ( Figure 1 ). The hydrodynamic diameter of the resulting PCN(Ni,As) increases to 121 ( 17 nm (ζ = À14.2 mV), while its arsenic-to-lipid ratio remains essentially unchanged (0.44 ( 0.04 mol/mol). As expected from our previous stability study of a similar dye-loaded system, 20 PCN(Ni,As) is also quite stable under biological pH and temperature, maintaining a constant hydrodynamic diameter over five days ( Figure S1 in the SI). Acid-Triggered Release of Ni II and As III from PCN(Ni,As). As our previously reported doxorubicin-encapsulated PCN has exhibited increased drug-release property under acidic conditions, 15 
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inside the liposomal core after the arsenous acid component diffuses out of the membrane. 6, 12 Interestingly, the apparent release rate of As III from PCN(Ni,As) was only about half of that from BL(Ni,As). We ascribed this to increased H-bonding interactions between the amphipathic arsenous acid (As(OH) 3 ), the fully protonated form of aqueous As III under acidic conditions, and the collapsed hydrophobic polymerÀlipid shell. This interaction is likely inhibiting the free diffusion of As III species into the surrounding media. As), BL(Ni,As), and free ATO for 48 h at 37°C before the apoptotic/dead cell populations were measured by annexin-V/7-AAD assay. 22 We observe a 1.7-fold higher apoptotic cell population (∼12.1 ( 2.3%, Figure 3A ) for HeLa cells treated with PCN(Ni,As) compared to those treated with BL(Ni,As) (∼7.0 ( 1.6% apoptotic population, Figure 3A) . As higher apoptotic cell populations can be correlated to higher susceptibilities of cancer cells toward a chemotherapeutic platform, this result suggests that PCN(Ni,As) should have enhanced therapeutic activity against tumors compared to BL(Ni,As).
The aforementioned results suggest that while less As III may be released from PCN(Ni,As) than from BL (Ni,As) under endosomal conditions, the concurrent release of Ni II from PCN(Ni,As) can cooperatively increase the pro-apoptotic activity of As III drugs, leading to a higher ratio of apoptotic-to-dead cells, and thus better efficacy, with PCN(Ni,As can lead to enhanced therapeutic behavior from a combination of enhanced endocytotic uptake 23 and concurrent release. PCN(Ni,As) may have an additional therapeutic benefit relative to BL(Ni,As) if the enhanced pro-apoptotic capability can be translated into in vivo reduced acute toxicity that causes detrimental side effects to patients. 
While PCN(Ni,As) is less cytotoxic than BL(Ni,As) at short incubation times, its cytotoxicity against HeLa cells approaches that of BL(Ni,As) as the cellular drugexposure time increases ( Figure S4 in the SI). At 10 μM [As III ], cells exposed to PCN(Ni,As) retain 99% cell viability after a 48 h incubation, less toxic than BL(Ni, As) (87% cell viability) and free ATO (83% cell viability, Figure 3B ). After 96 h of incubation, however, the cytotoxicity of PCN(Ni,As) (67% cell viability) is the same as that for BL(Ni,As) (69% cell viability). This phenomenon may be explained in part by the 2-fold slower release of As III from PCN(Ni,As) under acidic conditions compared to that from BL(Ni,As) ( Table 1 ). Assuming that both types of particles are taken up via endocytosis, 23, 25 the acidic environment of the endosome will result in a slower release of As III pharmacophore from PCN(Ni,As), which in turn leads to a lower cytotoxicity at shorter exposures. We suggest that the higher release rate of Ni II from PCN(Ni,As) ( Table 1) began to reduce the intracellular glutathione concentration during this period and gradually enhanced the ability of the small amount of As III agents available to induce apoptosis ( Figure 3A ). 26 The IC 50 values of PCN(Ni,As), BL(Ni,As), and free ATO against HeLa cells at different exposure times are listed in Table 2 , showing a progressively narrowing gap between the values for PCN(Ni,As) and those for BL(Ni,As) and free ATO as incubation time increases. This is not surprising given previous reports 12, 27 that nanoencapsulated drugs generally exhibit much attenuated initial in vitro toxicity compared to the free drugs due to the slower drug release kinetics from the carrier particles. The slow release of drugs from nanoencapsulated carriers in general has been suggested as one reason for the reduction of the acute toxicity of the parent drugs in vivo, 2,5 allowing for higher dosing with fewer detrimental side effects and thus better patient cure and survival. Indeed, several related packaged formulations exhibit lower in vitro toxicity compared to the free drugs and show excellent enhancements in in vivo therapeutic efficacies, 12, 28, 29 presumably via the well-known "enhanced permeation and retention (EPR)" effect. 30 Coupled to this reduction in acute toxicity, the improved combination of drugrelease property and the enhanced pro-apoptotic capability of PCN(Ni,As) suggests that this platform should have excellent potential for in vivo therapeutic activity. Understanding the pH-Dependent Release Property of the PCN(Ni,As) System via Computer Modeling of the Polymer Configuration. We previously attributed the acid-triggered drug-release property of the PCN platform to the pH-sensitive aggregation of the cross-linked polymer cage, 20 which is comprised of randomly distributed acrylic acid (AAc) and acrylamide (AAm) groups. This hypothesis was inspired by the known acidityinduced random-coil-to-globule phase transition of the random copolymer of acrylic acid and acrylamide, poly(AAc-r-AAm), in aqueous solution, 31 where the pHdependent ionization of the acrylic acid groups was shown to play a critical role in volume shrinkage of the polymer network, 32 following FloryÀHuggins theory. 33, 34 To further test this hypothesis, we carried out Monte Carlo (MC) simulations to compare the global minimum structures of amide-modified poly-(acrylate), a molecular analogue of our polymer cage ( Figure S5 in the SI), at two different pHs. A molecular model of a random copolymer composed of AAc and AAm groups (20-mers of each group, totaling 40 repeating units) was used to simulate the 24 Aqueous ATO (As 2 O 3 ) was used as a control (free As III ) in both experiments because metal arsenite complexes such as [Ni(HAsO 3 )] have very low solubility and cannot be dissolved in aqueous solution. 18 We note that the two assays cannot be directly compared; the annexin-V/7-AAD assay measured the proportions of apoptotic and dead cells in a culture, while the % cell viability in the MTS assay has to be measured against an external culture grown in the media as a control. Figure 4A , left conformation), which is a good measure of the ensemble average of polymer size. 36 In sharp contrast, the polymer is substantially collapsed at low pH, with a reduced R G of only 11.6 Å ( Figure 4A , right conformation). This nanoscale change in conformation arises from increased intramolecular hydrogen bonds between the pendant groups on a single polymer backbone (and also between chains) under acidic conditions (indicated by red lines in Figure 4A , right conformation). Molecular dynamics (MD) simulations of the aforementioned model polymer chains further support the MC results: at pH 7.4 and 300 K, the deprotonated poly(AAc-r-AAm) exhibits a calculated R G of 20.5 ( 0.8 Å (see additional discussion below), which is reduced to 11.8 ( 0.3 Å at pH 5.0. When many of these polymer chains are cross-linked together across the whole liposomal membrane, their acid-triggered conformational collapse cooperatively creates a dense network of pressured points that "squeezes" the liposome ( Figure 4B,C) , greatly destabilizing the lipid bilayer membrane and leading to a significant enhancement of drug release from the liposomal core. 37 Without the cross-linking between chains, acid-triggered conformational change of the individual polymer chains can only result in relatively small "point defects" on the membrane rather than a concerted destabilization of liposome via the "squeezing" action of the densified polymer cage.
Testing the Model via Temperature Changes. Poly(AAc-rAAm) is well-known to exhibit thermosensitive swelling/shrinking behavior, a property that arises from its lower critical solution temperature (LCST), which ranges between 30 and 40°C. 31, 38 At LCST, this copolymer undergoes a temperature-dependent randomcoil-to-globule phase transition induced by the segregation of polymer chains from the surrounding water molecules. As a result, the increased intermolecular hydrophobic interactions between the polymer chains above the LCST eventually lead to the globular aggregation of polymer networks out of the aqueous solution. We hypothesize that such thermally driven swelling/shrinking behavior may also occur as a function of temperature in our model poly(AAc-r-AAm) chain and can be observed computationally. 
Molecular dynamics simulations were thus carried out with the aforementioned poly(AAc-r-AAm) model polymer as a molecular analogue for our polymer cage under neutral aqueous conditions and at either 290 or 330 K. As expected, the R G population of the polymer chain varies inversely as a function of temperature: the average R G at 290 K was found to be 22.4 ( 1.1 Å ( Figure  5A ), decreasing to 20.5 ( 0.9 Å at 330 K ( Figure 5B ). Although this temperature-dependent change in R G was relatively small (ΔR G = 1.9 Å over a 40 K range) compared to the aforementioned pH-induced size change (ΔR G = 7.5 Å over a 2.4 pH unit change), these results clearly support the temperature-sensitive shrinking property of the cross-linked polymer cage in our PCN platform.
Experimental Tests of Predicted PCN Size Changes in Response to Thermal and pH Stimuli. To test the aforementioned predicted pH-and temperature-induced size changes of the PCN platform, we compared the hydrodynamic diameter of a model empty liposome system, BL(emp), against that of an empty PCN, PCN(emp), under various stimulus conditions using dynamic light scattering. At pH 7.4 and 25°C, the mean D H of this PCN(emp) was 121 ( 25 nm. This value decreased to 108 ( 27 nm when the temperature was increased to 37°C (blue dotted arrow in Figure 6A ), as predicted by our MD simulations. Consistent with the analogy of a phase transition, a separate temperature-variation experiment showed the mean D H of our PCN(emp) model system being constant (118 ( 11 nm) in the 10À30°C range, undergoing ∼20% decrease (D H = 99 ( 9 nm) as the temperature is increased above 40°C, and then remaining constant at the smaller value up to 80°C ( Figure 6B ). In stark contrast, the parent BL(emp) system exhibits only an insignificant diameter expansion that is typically observed with temperature increase over the same temperature range. Given the highly stable nature of the lipid membranes used in our model systems (containing 40 mol % of cholesterol, which eliminates the melting transition of the lipid bilayer 39 ), the decrease of the PCN(emp)'s D H above 40°C can be attributed solely to the conformational change of its outer polymer cage. As predicted from our MD simulations, the relatively small change in R G upon temperature variation (ΔR G = 1.9 Å, ∼10%) is not enough of a driving force to result in PCN membrane rupture. Not surprisingly, this thermally induced conformational change in the polymer cage is completely reversible without hampering the membrane integrity of PCN ( Figure 6C ). The Ni II -to-lipid and As III -to-lipid ratios in PCN(Ni,As) samples that were incubated at 40°C for 2 h are the same as those for PCN(Ni,As) samples that were incubated at 25°C ( Figure S6 in the SI), further confirming that there was minimum drug leakage from PCN(Ni,As) when its size becomes smaller at the higher temperature.
Given that the polymer cage in our model PCN(emp) system resembles a cross-linked network of poly(AAc-rAAm), a large change in D H should be observed when the solution becomes acidic. 40 At 37°C, the D H of PCN(emp) further decreased to 69 ( 39 nm upon acidification to pH 5.5 (from pH 7.4, purple arrow in Figure 6A ). Longer incubation at pH 5.5 and 37°C further decreased the D H of PCN(emp) to 49 ( 26 nm (red arrow in Figure 6A ). Consistent with our modeling results, these pH-induced changes in PCN size are much larger than the thermally induced changes and can significantly affect the stability of the caged liposome, eventually leading to its rupture and observed enhancements in drug-release. Indeed, as shown in the first part of this paper, the pH-sensitive polymer cage of PCN is the main contributor to the concurrent release of both Ni II and As III agents from a liposomal core, in stark contrast to the sole release of As III from BL(Ni,As).
CONCLUSION
In conclusion, the versatile tunable release property of the PCN platform can be attributed to the pH-and temperature-responsive conformation change of a cross-linked polymer network on the nanoscale: this is corroborated by computational modeling studies and verified in PCN model systems. As demonstrated here, the resulting concurrent release of multiple chemotherapeutic agents can lead to improved therapeutic index, 
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where Ni II ions can cooperatively enhance the proapoptotic activity of arsenic trioxide while reducing its detrimental side effects. The ability to acid-trigger the release of a combination of drugs co-encapsulated in a single nanoparticle via chemomechanical perturbation of a modified liposomal membrane is a key feature that enhances PCN as a drug delivery platform, particular for disease sites that have low pH's. The delivery of anticancer drugs to hypoxic, acidic tumor tissues using the PCN platform provides several advantageous features relative to bare liposome, and we anticipate that they will be effective for delivering a variety of drugs 41 to cancer cells that take up nanoparticles via an endocytotic pathway and process them through acidic lysosomes.
MATERIALS AND METHODS
Materials. Unless otherwise noted, all reagents and materials were purchased from commercial sources and used as received. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) and 1,2-dioleoyl-sn-glycero-3-[phospho-rac-(1-glycerol)] (sodium salt) (DOPG) were purchased from Avanti Polar Lipids (Alabaster, AL). ICP calibration standard solutions of phosphorus (1000 μg/ mL P), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide methiodide (EDC 3 MeI), 2,2 0 -(ethylenedioxy)bis(ethyleneamine), and all other reagents were purchased from Aldrich Chemical Co. (Milwaukee, WI). Cholesterol-terminated poly(acrylic acid) was prepared using a literature procedure. 20 Ultrapure deionized (DI) water was obtained from a Millipore system (18.2 MΩ cm resistivity).
Instrumentation. Fourier-transformed nuclear magnetic resonance (NMR) spectroscopy was performed on a Varian INOVA-500 MHz spectrometer ( UVÀvis absorption spectra were obtained on a CARY 300 Bio UVÀvis spectrophotometer.
Electrospray-ionization mass spectrometric (ESIMS) data were obtained on a Micromass Quattro II triple quadrupole mass spectrometer. Phosphorus, arsenic, and nickel concentrations of the synthesized liposome and PCN materials and of the Sephadex-eluted liposome fractions in benchtop-release experiments were determined using a Varian Vista MPX simultaneous inductively coupled plasma optical emission (ICP-OES) spectrometer.
Polymer molecular weight of the cholesterol-terminated poly(tert-butyl acrylate) was measured relative to polystyrene standards on a Waters gel-permeation chromatograph equipped with Breeze software, a 717 autosampler, a Shodex KF-G guard column, KF-803 L and KF-806 L columns in series, a Waters 2440 UV detector, and a 410 RI detector. HPLC-grade THF was used as an eluent at a flow rate of 1.0 mL/min, and the instrument was calibrated using polystyrene standards (Aldrich, 15 standards, 760À1 800 000 Da).
Dynamic light scattering and zeta potential measurements were performed on a Zetasizer Nano ZS (Marvern Instruments, Malvern, UK) with a HeÀNe laser (633 nm). The noninvasive backscatter method (detection at 173°scattering angle) was used. Correlation data were fitted, using the method of cumulants, to the logarithm of the correlation function, yielding the diffusion coefficient, D. 6 DPPC (108.29 μmol), DOPG (6.91 μmol), and cholesterol (76.8 μmol, 40 mol % of the total membrane components; this number is chosen to eliminate the thermal instability of the liposomes that is attributable to the intrinsic phase-transition temperature of the lipid) were added to a 20 mL cylindrical glass vial, followed by chloroform (5 mL) to make a colorless solution. After vortexing (∼1 min), the solvent was removed by passing a stream of nitrogen over the solution while the vial was warmed in a 50°C water bath. The resulting dry film was further dried under vacuum on a Schlenk line (<30 mTorr) overnight. Next, the dry lipid films were hydrated in 300 mM aqueous [Ni(CH 3 COO) 2 ] solution (5 mL) followed by vigorous vortexing (3À5 min on a Vortex Mixer, American Scientific Products) to form a dispersion of multilamellar vesicles. After this dispersion was subjected to 10 freezeÀthaw cycles, it was extruded 10 times through two stacked polycarbonate extrusion membranes (100 nm pore size) that are maintained at 50°C in a LIPEX extruder (Northern Lipids Inc., Burnaby, BC, Canada). The excess [Ni(CH 3 COO) 2 ] outside of the liposome was removed by Sephadex G-50 (50 mL) gel-filtration chromatography pre-equilibrated with 150 mM NaCl solution. Aqueous arsenic trioxide (ATO, 0.5 equiv of the total lipid content) solution was added to the collected liposome solution (∼5 mL of a solution with ∼4 mM lipid concentration) and incubated at 50°C for 3 h. The excess ATO outside of the liposome was then removed by Sephadex G-50 (50 mL) gelfiltration chromatography pre-equilibrated with 20 mM HEPES buffers (pH 7.4, 150 mM NaCl). ]-loaded bare liposomes, BL(Ni,As), were next subjected to the PCN fabrication process as reported previously. 20 For this process, 10 mol % of the cholesterol-terminated poly-(acrylic acid) (Chol-PAA, M n ≈ 3700 Da) was chosen to maximize the amount of the modifier while preventing local phase-segregation of all the cholesterol in the membrane. Next, 50% of acrylate repeating units in Chol-PAA chains was cross-linked with diamine cross-linker. Mean D H of 125 ( 14 nm and À14.2 mV of zeta potential were determined by DLS measurements. To measure the stimuli-sensitive diameter change of PCN particles, the same preparation method described above was carried out with an empty bare liposome template.
[Ni II , As III ]-Release Assay from PCN(Ni,As). PCN(Ni,As) solutions (1 mM, 2 mL) were added into a semipermeable dialysis tube (molecular weight cutoff 10 kDa) and dialyzed against either 20 mM acetate buffer (pH 4.0, 150 mM NaCl) or 20 mM HEPES buffer (pH 7.4, 150 mM NaCl) at 37°C with stirring. An aliquot of the PCN(Ni,As) was collected at a predetermined time, and the Ni II , As III , and lipid (P) contents were measured by ICP-OES. The extent of drug release was observed by comparing timedependent change of Ni II /P and As III /P molar ratios to the initial values.
Cell Culture. a. Media and Cell Culture Reagents. Eagle's minimum essential medium (EMEM) was purchased from ATCC ARTICLE (Manassas, VA), and trypsin solution (0.25%, containing EDTA) was purchased from Invitrogen (San Diego, CA). Fetal bovine serum (FBS), penicillinÀstreptomycin, and phosphate-buffered saline (PBS, 1Â without calcium and magnesium) solutions were purchased from Mediatech (Manassas, VA).
b. Cell Lines and Conditions. HeLa human cervical cancer cells (CCL-2) were purchased from American Type Culture Collection (ATCC, Manassas, VA). HeLa cells were continuously cultured in EMEM supplemented with 10 vol % heat-inactivated FBS and 0.5 vol % penicillinÀstreptomycin solution at 37°C in a humidified atmosphere containing 5% CO 2 .
Cytotoxicity Assays. The cells (20 000) were seeded into 96-well plates (100 μL/well). The plates were then incubated under the cell culture conditions, and the cells were allowed to grow to confluence for 24 h. The media in the wells was replaced with the preprepared growth media containing the appropriate drug formulation (100 μL of solution at the appropriate As III concentrations). The drug-treated cells were incubated for either 48, 72, or 96 h under the cell culture conditions, after which the cells were washed with PBS buffer (2 Â 150 μL). The cell viabilities were then measured by the MTS cell proliferation assay, and the relative cell survival percentages compared to the drug-free control were plotted against the drug concentration in logarithmic scale. The data reported represent an average of three measurements from different batches. The doseÀ effect profiles were obtained by sigmoidal logistic fitting using Origin 6.1 (OriginLab, Northampton, MA), and the half-maximal inhibitory concentration (IC 50 ) values were determined on the basis of the fitted data.
Apoptosis Assay. Flow cytometry with a Guava Nexin Apoptosis Assay kit (annexin V-PE/7-AAD, Millipore) was used to determine apoptotic cell populations. HeLa cells (100 000) were seeded into a 24-well tissue culture plate and incubated for 24 h under standard growth conditions. Cell-growth media was then replaced with fresh media including PCN(Ni,As), BL(Ni,As), or ATO ([As III ] = 10 μM for each drug formulation). The drugtreated cells were incubated for 48 h under the cell culture conditions, after which the cells were washed with PBS buffer. The cells were then detached by harvesting with 0.25% trypsin-EDTA solution and subsequently stained by the Guava Nexin reagent. Then, the apoptotic cell population was measured using a Guava EasyCyte Mini flow cytometer. The data reported represent an average of three measurements from different batches.
Molecular Modeling. a. Monte Carlo Simulation. The AMBER* parameters implemented in Macromodel 6.0 42 were used for the Monte Carlo conformational search 35 and molecular mechanics calculations of the polymer shown in Figure 4 to obtain the minimum energy structures. The GB/SA method 43 is used for simulating water solvent, and the number of structures tried in the conformational search was 1000. Energy minimization based on the conjugate gradient algorithm was then performed on every sampled structure to a gradient norm of less than 0.01 kJ 3 mol À1 Å
À1
. b. Molecular Dynamics Simulations. Molecular dynamics simulations of the polymer shown in Figure 4 at virtual pH 7.4 and either 290 or 330 K;as well as at virtual pH 5.0 or 7.4 at 300 K; were performed using the Monte Carlo/Stochastic Dynamics (MC/SD) 44 method implemented in Macromodel 6.0. A production simulation was performed for 1 ns after 10 ps equilibration with a 1 fs time step. The GB/SA method was again used for simulating water solvent, and atomic coordinates were saved every 1 ps for the calculation of the radius of gyration.
